Bobby J. King, Jr.
President
Sircle Laboratories, LLC
P.O. Box 238
Ridgeland , MS 39158
United StatesFEI 3011772828Issued Sep 21, 2021Office of Pharmaceutical Quality Operations, Division II
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3011772828.
Violations3
Issue DateSep 21, 2021
Product TypeDrugs
StatusOpen
Letter Details
Firm
Sircle Laboratories, LLC
Location
Bobby J. King, Jr.
President
Sircle Laboratories, LLC
P.O. Box 238
Ridgeland , MS 39158
United States
FEI Number
3011772828
Country
United States
Issue Date
September 21, 2021
Issuing Office
Office of Pharmaceutical Quality Operations, Division II
Product Type
Drugs
Status
Open
Summary
Sircle Laboratories, LLC manufactured adulterated drug products due to significant Current Good Manufacturing Practice (CGMP) violations identified during an April 2021 FDA inspection of its Madison, Mississippi facility. The company's quality control unit failed to exercise adequate oversight and responsibility to ensure drug products met established specifications for identity, strength, quality, and purity, and the firm lacked appropriate procedures to manage contract manufacturing organizations (CMOs) used for manufacturing, packaging, and distribution. The company failed to follow its own established quality unit procedures and commitments documented in quality agreements, with particular deficiencies in oversight and controls for its CMOs, which resulted in the use of sub-standard contractors.
Sircle Laboratories, LLC FDA Warning Letter, September 21, 2021